Preliminary Hemodynamic Report of the Efficacy and Safety of Quinapril in Acute and Chronic Treatment of Patients with Congestive Heart Failure

26 patients with congestive heart failure (NYHA Class III or IV) who had not optimally responded to treatment with diuretics and digitalis.

Quinapril hydrochloride (acute single doses of 2.5, 5, or 10 mg, followed by chronic individualized doses of 5 to 30 mg/day for 16 weeks).

Changes in four primary hemodynamic parameters (mean arterial blood pressure, pulmonary capillary wedge pressure, cardiac output, and systemic vascular resistance) compared with baseline.surrogate